PCN67 Estimating Cost-Effectiveness of Pembrolizumab in Advanced Esophageal Cancer Based on the Keynote-181 Trial

Abstract

Authors

J. Silvers J. Carlson

Full Text Cite This Article
Back to Volume 24, Supplemental S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×